Analysis Alterity Therapeutics Limited (PRNAF)
6/2/2024
Analysis of Alterity Therapeutics Limited (PRNAF)
Alterity Therapeutics Limited (PRNAF) has been trading at a consistent price of 0.00020. The RSI indicator is at 0.00000, indicating a neutral momentum. The MACD indicator is slightly negative, with the MACD line below the signal line, suggesting a potential bearish trend.In terms of moving averages, the Simple Moving Average (SMA), Exponential Moving Average (EMA), and Weighted Moving Average (WMA) are all around 0.00020 to 0.00024, indicating stability in the short term.
Overall, based on the current data, Alterity Therapeutics Limited seems to be trading in a tight range with no significant price movements or clear trend direction. Traders and investors may want to wait for more decisive signals before making any trading decisions.
Revenue estimate
Based on the analysts' estimates for the future quarterly and annual sales of the company, we can draw the following conclusions:1. For the current quarter ending on June 30, 2024, the average sales estimate is $77,545,400,000, with a sales growth of 2% compared to the same quarter last year. The number of analysts providing estimates is 25.
2. For the next quarter ending on September 30, 2024, the average sales estimate is $85,501,800,000, with a sales growth of 3% compared to the same quarter last year. The number of analysts providing estimates is 25.
3. For the current fiscal year ending on September 30, 2024, the average sales estimate is $357,772,000,000, with a sales growth of 1% compared to the previous fiscal year. The number of analysts providing estimates is 38.
4. For the next fiscal year ending on September 30, 2025, the average sales estimate is $380,772,000,000, with a sales growth of 6% compared to the current fiscal year. The number of analysts providing estimates is 38.
Overall, the analysts are generally optimistic about the company's future sales performance, with moderate growth expected in both the quarterly and annual sales figures.
Growth estimates
Based on the consensus estimates provided by analysts, we can draw the following conclusions regarding the growth rate of the company for different periods:1. Current Quarter: The estimated growth rate for the current quarter is 5.1%.
2. Next Quarter: The estimated growth rate for the next quarter is 5.2%.
3. Current Year: The estimated growth rate for the current year is 7.6%.
4. Next Year: The estimated growth rate for the next year is 9.7%.
5. Past 5 Years (per annum): The average annual growth rate for the past 5 years is 20.1%.
6. Next 5 Years (per annum): The estimated average annual growth rate for the next 5 years is 9.7%.
These estimates suggest a positive growth trend for the company, with a slight decrease in growth rate from the past 5 years to the next 5 years. However, the company is still expected to experience healthy growth in the upcoming periods according to analyst consensus.
Price target
The analysts' forecast for the future price of the security is as follows:- Low: $164
- High: $275
- Median: $201.43
- Average: $204.58
- Current price: $192.25
- Currency: USD
Based on these forecasts, we can see that the analysts have a wide range of opinions on the future price of the security, with the low end being $164, the high end being $275, and the average forecast at $204.58. The current price of the security is $192.25, which is below the median and average forecast, indicating that there is some optimism among analysts for the security to increase in value.
Earnings
The company's results for the most recent quarter, ending on April 30, 2025, have not been provided at this time. The previous quarter's results, ending on February 27, 2025, were handled by the Transfer Agent. The quarter before that, ending on January 31, 2025, had results released after hours. The results for the quarter ending on October 31, 2024, were not provided at the time. However, for the quarter ending on August 1, 2024, the company had an EPS estimate of 1.32.Main Statystic ðŸ§
The data provided includes financials, stock statistics, valuation metrics, stock price summary, and dividends and splits information for a specific company.In terms of financials, the company has a strong operating cash flow and levered free cash flow. The balance sheet shows a healthy current ratio, but a relatively high total debt to equity ratio. The profit margin and operating margin are both positive, indicating profitability. The company's fiscal year ends in September 2023, with notable figures such as EBITDA, revenue, and net income.
Moving on to stock statistics, key metrics include short ratio, float shares, shares outstanding, and percentages held by insiders and institutions. The valuation metrics reveal important ratios like PEG ratio, PE ratios, enterprise value, and market capitalization. The stock price summary includes beta, moving averages, and the range of the stock price over the past year.
Lastly, the dividends and splits section provides details on payout ratio, dividend dates, split history, and dividend yields. This comprehensive set of data offers insights into the financial health, market performance, and dividend policy of the company.
Income statement 💸
These are the revenues. Draw conclusions.Balance Sheet
These are balance sheets. Here are the conclusions:1. The total assets have been increasing over the years, reaching $365,725,000,000 in 2018.
2. Current assets fluctuate, with the highest value in 2019 at $162,819,000,000.
3. Non-current assets have been increasing steadily, with the highest value in 2019 at $175,697,000,000.
4. Total liabilities have also been increasing, reaching $255,355,000,000 in 2018.
5. Shareholders' equity has been fluctuating, with the highest value in 2018 at $107,147,000,000.
Cash Flow 💶
This is the cash flow statement. Here are some conclusions we can draw from the data:1. The company's free cash flow has been fluctuating over the years, with the highest value in 2022 and the lowest in 2020.
2. Operating cash flow has generally been increasing year over year, indicating improved operational efficiency.
3. Financing activities show significant fluctuations, with large amounts being spent on common stock repurchase and debt issuance/payment.
4. Investing activities also vary, with notable amounts spent on the sale and purchase of investments.
5. The end cash position has been relatively stable, with some fluctuations due to the company's financial activities.
6. Interest paid and income tax paid have also shown variations over the years, impacting the company's cash flow position.
Earnings estimate
Based on the analysts' estimates for future quarterly and annual earnings per share:1. For the current quarter ending on June 30, 2024, the average EPS estimate is $1.23, with a low estimate of $1.18 and a high estimate of $1.26. This shows growth compared to the EPS of $1.17 from the same quarter a year ago.
2. For the next quarter ending on September 30, 2024, the average EPS estimate is $1.42, with a low estimate of $1.33 and a high estimate of $1.51. This indicates an increase from the EPS of $1.35 from the same quarter last year.
3. For the current year ending on September 30, 2024, the average EPS estimate is $6.10, with a low estimate of $5.95 and a high estimate of $6.41. This reflects growth compared to the EPS of $5.67 from the previous year.
4. Looking ahead to the next year ending on September 30, 2025, the average EPS estimate is $6.69, with a low estimate of $5.92 and a high estimate of $7.31. This suggests a potential increase from the EPS of $6.10 for the current year.
Overall, the analysts are forecasting growth in earnings per share for both the upcoming quarters and the next fiscal year.
MACD of PRNAF
This is not investment advice. Remember to verify the information provided here.
Get access to the full analysis
- Over 35 000 indexes
- CFD, Forex, Crypto and Stocks Exchange
- Over 150 Indicators
- Pattern and candle analysis
- Support and resistance levels
- Fundamental, technical and sentimental analysis
- Power from AI
